Intellia Therapeutics Inc

Intellia Therapeutics shares surged 23% to $14.92 after Phase 3 data showed lonvo-z reduced hereditary angioedema attacks by up to 91% versus placebo, with FDA filing as the next catalyst.

CRISPR Therapeutics shares surged 12% in New York trading, buoyed by a sector-wide gene-editing rally and Eli Lilly's $1.9 billion deal with Ascidian Therapeutics.

Intellia Therapeutics (NTLA) announced its CRISPR therapy lonvo-z cut HAE attacks by 87% vs placebo in a Phase 3 trial, with 62% of patients attack-free. A rolling FDA submission has begun.

Intellia Therapeutics shares rallied 19.3% after hours Friday as investors await Phase 3 data from its HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR gene-editing therapy for hereditary angioedema.